AZURE subgroup analysis shows adjuvant therapy with zoledronic acid may benefit breast cancer patients postmenopausal >5 years.

Anonymous

首页> 外文期刊>Oncology >AZURE subgroup analysis shows adjuvant therapy with zoledronic acid may benefit breast cancer patients postmenopausal >5 years.

【24h】

AZURE subgroup analysis shows adjuvant therapy with zoledronic acid may benefit breast cancer patients postmenopausal >5 years.

机译：AZURE亚组分析显示，唑来膦酸辅助治疗可能会使绝经后大于5年的乳腺癌患者受益。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Reporting complete results of the AZURE trial online in the New England Journal of Medicine on September 25, researchers concluded that the bisphosphonate zoledronic acid (Zometa [ZA]) should not be used routinely in adjuvant management of breast cancer. In what they described as an "intriguing" finding, however, small improvements in disease-free and overall survival (DFS, OS) were seen with the addition of ZA to adjuvant therapy in a subgroup of early-stage breast cancer patients who had been postmenopausal for more than 5 years.

机译：研究人员于9月25日在《新英格兰医学杂志》上在线报道了AZURE试验的完整结果，研究人员得出结论，双膦酸盐唑来膦酸（Zometa [ZA]）不应常规用于乳腺癌的辅助治疗。然而，在他们所说的“有趣”发现中，在早期乳腺癌患者的亚组中，在辅助治疗中添加了ZA可以看到无病生存期和总体生存期（DFS，OS）的小幅改善。绝经5年以上。

著录项

来源
《Oncology》 |2011年第12期|共2页
作者
Anonymous;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. AZURE subgroup analysis shows adjuvant therapy with zoledronic acid may benefit breast cancer patients postmenopausal >5 years. [J] . Anonymous Oncology . 2011,第12期

机译：AZURE亚组分析显示，唑来膦酸辅助治疗可能会使绝经后大于5年的乳腺癌患者受益。
2. Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04) [J] . R.E. Coleman, M. Collinson, W. Gregory, Journal of Bone Oncology . 2018,第4期

机译：唑来膦酸辅助治疗II / III期乳腺癌的益处和风险。 AZURE随机临床试验的10年随访（BIG 01/04）
3. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. [J] . Coleman R, Woodward E, Brown J, Breast cancer research and treatment. . 2011,第2期

机译：一项针对II / III期乳腺癌女性的随机III期试验（AZURE：BIG 01-04）在佐剂治疗期间唑来膦酸的安全性和颌骨骨坏死的发生率。
4. Radium-223 Dichloride Monotherapy and Combination Therapy with Zoledronic Acid or Doxorubicin Improve Survival in a Mouse Model of Breast Cancer Bone Metastasis [C] . Jukka Rissanen, Mari Suominen, Rami K?k?nen, Molecular Medicine TRI-CON. . 2014

机译：镭-223二氯化物单疗法和组合治疗唑醇或多柔比星改善了乳腺癌骨转移的小鼠模型中的存活
5. Subgroup analysis based on prognostic and predictive gene signatures for adjuvant chemotherapy in early-stage non-small-cell lung cancer patients [D] . Pluta, Dustin. 2015

机译：基于预后和预测基因特征的亚组分析用于早期非小细胞肺癌患者的辅助化疗
6. Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04) [O] . R.E. Coleman, M. Collinson, W. Gregory, 2018

机译：唑来膦酸辅助治疗II / III期乳腺癌的益处和风险。 AZURE随机临床试验的10年随访（BIG 01/04）
7. Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04) [O] . R.E. Coleman, M. Collinson, W. Gregory, 2018

机译：在II / III阶段乳腺癌中Zoledronic酸的辅助治疗的益处和风险。 10年的Azure随机临床试验随访（Big 01/04）

AZURE subgroup analysis shows adjuvant therapy with zoledronic acid may benefit breast cancer patients postmenopausal >5 years.

摘要

著录项

相似文献

相关主题

期刊订阅